1. |
Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China. Lancet Oncol, 2014, 15(7): e279-e289.
|
2. |
Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin, 2011, 61(4): 212-236.
|
3. |
Dawood S. Triple-negative breast cancer: epidemiology and management options. Drugs, 2010, 70(17): 2247-2258.
|
4. |
Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature, 2000, 406(6797): 747-752.
|
5. |
Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res, 2009, 69(10): 4116-4124.
|
6. |
Penault-Llorca F, Viale G. Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective. Ann Oncol, 2012, 23(Suppl 6): vi19-vi22.
|
7. |
Brenton JD, Carey LA, Ahmed AA, et al. Molecular classification and molecular forecasting of breast cancer: ready for clinical application?. J Clin Oncol, 2005, 23(29): 7350-7360.
|
8. |
Badve S, Dabbs DJ, Schnitt SJ, et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol, 2011, 24(2): 157-167.
|
9. |
Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer, 2007, 109(1): 25-32.
|
10. |
Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest, 2011, 121(7): 2750-2767.
|
11. |
Gusterson A, Ross T, Heath J, et al. Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res, 2005, 7(4): 143-148.
|
12. |
Kim MJ, Ro JY, Ahn SH, et al. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol, 2006, 37(9): 1217-1226.
|
13. |
Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol, 2007, 8(3): 235-244.
|
14. |
Turner C, Reis-Filho S, Russell M, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene, 2007, 26(14): 2126-2132.
|
15. |
Abd El-Rehim DM, Ball G, Pinder SE, et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer, 2005, 116(3): 340-350.
|
16. |
Gangi A, Chung A, Mirocha J, et al. Breast-conserving therapy for triple-negative breast cancer. JAMA Surg, 2014, 149(3): 252-258.
|
17. |
Moran MS. Radiation therapy in the locoregional treatment of triple-negative breast cancer. Lancet Oncology, 2015, 16(3): E113-E122.
|
18. |
Pilewskie M, Ho A, Orell E, et al. Effect of margin width on local recurrence in triple-negative breast cancer patients treated with Breast-Conserving therapy. Ann Surg Oncol, 2014, 21(4): 1209-1214.
|
19. |
Gangi A, Mirocha J, Leong T, et al. Triple-negative breast cancer is not associated with increased likelihood of nodal metastases. Ann Surg Oncol, 2014, 21(13): 4098-4103.
|
20. |
Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res, 2007, 13(8): 2329-2334.
|
21. |
Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol, 2008, 26(8): 1275-1281.
|
22. |
Symmans F, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol, 2007, 25(28): 4414-4422.
|
23. |
Hugh J, Hanson J, Cheang MC, et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol, 2009, 27(8): 1168-1176.
|
24. |
Isakoff SJ. Triple-negative breast cancer role of specific chemotherapy agents. Cancer J, 2010, 16(1): 53-61.
|
25. |
Printz C. I-SPY2 trial yields first results on combination therapy for triple-negative breast cancer. Cancer, 2014, 120(6): 773.
|
26. |
Sikov M, Berry A, Perou M, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage Ⅱ to Ⅲ triple-negative breast cancer: CALGB 40603 (Alliance) . J Clin Oncol, 2015, 33(1): 13-21.
|
27. |
Von Minckwitz G, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol, 2014, 15(7): 747-756.
|
28. |
Koshy N, Quispe D, Shi R, et al. Cisplatin-gemcitabine therapy in metastatic breast cancer: improved outcome in triple negative breast cancer patients compared to non-triple negative patients. Breast, 2010, 19(3): 246-248.
|
29. |
Zhang J, Wang ZH, Hu XC, et al. Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer. Int J Cancer, 2015, 136(1): 204-211.
|
30. |
Kotsori AA, Dolly S, Sheri A, et al. Is capecitabine efficacious in triple negative metastatic breast cancer?. Oncology, 2010, 79(5/6): 331-336.
|
31. |
Rivera E, Lee J, Davies A. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors. Oncologist, 2008, 13(12): 1207-1223.
|
32. |
Perez A, Patel T, Moreno-Aspitia A. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer. Breast Cancer Res Treat, 2010, 121(2): 261-271.
|
33. |
Tredan O, Campone M, Jassem J, et al. Ixabepilone alone or with cetuximab as First-Line treatment for advanced/metastatic triple-negative breast cancer. Clin Breast Cancer, 2015, 15(1): 8-15.
|
34. |
Telli ML, Jensen KC, Vinayak S, et al. Phase Ⅱ study of gemcitabine, carboplatin, and iniparib as neoadjuvant therapy for triple-negative and BRCA1/2 mutation-associated breast cancer with assessment of a tumor-based measure of genomic instability: PrECOG 0105. J Clin Oncol, 2015, 33(17): 1895-1901.
|
35. |
O’shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med, 2011, 364(3): 205-214.
|
36. |
O’shaughnessy J, Schwartzberg L, Danso A, et al. Phase Ⅲ study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol, 2014, 32(34): 3840-3847.
|
37. |
Corkery B, Crown J, Clynes M, et al. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol, 2009, 20(5): 862-867.
|
38. |
Perez EA, Spano JP. Current and emerging targeted therapies for metastatic breast cancer. Cancer, 2012, 118(12): 3014-3025.
|
39. |
Cameron D, Brown J, Dent R, et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (Beatrice): primary results of a randomised, phase 3 trial. Lancet Oncol, 2013, 14(10): 933-942.
|